Plasma Aβ as a biomarker for predicting Aβ-PET status in Alzheimer’s disease：a systematic review with meta-analysis

A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis

(2021) Tim West et al.   Molecular Neurodegeneration

Plasma Amyloid-β Oligomerization Tendency Predicts Amyloid PET Positivity

(2021) Jung-Min Pyun et al.   Clinical Interventions in Aging

Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease

(2021) Shorena Janelidze et al.   JAMA Neurology

Total Aβ42/Aβ40 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis

(2020) James D. Doecke et al.   NEUROLOGY

The combined effects of microglia activation and brain glucose hypometabolism in early-onset Alzheimer’s disease

(2020) Giacomo Tondo et al.   Alzheimers Research & Therapy

Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease

(2019) Andrea Vergallo et al.   Alzheimers & Dementia

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

(2019) Oskar Hansson et al.   Alzheimers Research & Therapy

Brain Amyloid-β Deposition and Blood Biomarkers in Patients with Clinically Diagnosed Alzheimer’s Disease

(2019) Wei-Wei Li et al.   JOURNAL OF ALZHEIMERS DISEASE

High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis

(2019) Suzanne E. Schindler et al.   NEUROLOGY

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease

(2019) Sebastian Palmqvist et al.   EMBO Molecular Medicine

Ultrasensitive Detection of Plasma Amyloid-β as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer’s Disease

(2019) Pratishtha Chatterjee et al.   JOURNAL OF ALZHEIMERS DISEASE

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease

(2018) Clifford R. Jack et al.   Alzheimers & Dementia

High performance plasma amyloid-β biomarkers for Alzheimer’s disease

(2018) Akinori Nakamura et al.   NATURE

Multiplex immunoassay measurement of amyloid-β42 to amyloid-β40 ratio in plasma discriminates between dementia due to Alzheimer’s disease and dementia not due to Alzheimer’s disease

(2018) Jonathan Vogelgsang et al.   EXPERIMENTAL BRAIN RESEARCH

Tau passive immunization inhibits not only tau but also Aβ pathology

(2017) Chun-ling Dai et al.   Alzheimers Research & Therapy

Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial

(2016) Serge Gauthier et al.   LANCET

Alzheimer's disease

(2016) Philip Scheltens et al.   LANCET

CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

(2016) Bob Olsson et al.   LANCET NEUROLOGY

Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study

(2015) Osama Sabri et al.   Alzheimers & Dementia

Alzheimer’s disease cerebrospinal fluid biomarker in cognitively normal subjects

(2015) Jon B. Toledo et al.   BRAIN

Aβ42 and Aβ40: similarities and differences

(2015) Tian Qiu et al.   JOURNAL OF PEPTIDE SCIENCE

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

Novel plasma biomarker surrogating cerebral amyloid deposition

(2014) Naoki KANEKO et al.   PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES

Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker

(2013) Jon B Toledo et al.   Alzheimers Research & Therapy

Plasma Amyloid-β as a Predictor of Dementia and Cognitive Decline

(2012) Alain Koyama et al.   ARCHIVES OF NEUROLOGY

Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease

(2012) Randall J. Bateman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

(2010) Kaj Blennow et al.   Nature Reviews Neurology

Review: Sporadic cerebral amyloid angiopathy

(2010) J. Attems et al.   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

Cerebrospinal Fluid β-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain

(2009) Tero Tapiola et al.   ARCHIVES OF NEUROLOGY